Bavarian Nordic A/S announced that the financial guidance for the full year has been upgraded six times since March 2022 as result of multiple supply contracts being entered since the start of the monkeypox outbreak in May. The most recent guidance, issued on July 18, is maintained at revenues between DKK 2,700 million and 2,900 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
180.8 DKK | -0.85% | -2.22% | +1.86% |
31/05 | Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine | MT |
30/05 | Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.86% | 2.07B | |
+45.99% | 754B | |
+40.95% | 630B | |
-6.03% | 352B | |
+19.70% | 331B | |
+9.50% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+6.05% | 164B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022